Compare Amphastar Pharmaceuticals Inc (AMPH) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs T Rowe Price Group Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while T Rowe Price Group Inc trades at $118.55 (market cap $25.40B). The key difference: T Rowe Price Group Inc is far larger — about 30.7× Amphastar Pharmaceuticals Inc's market cap, and T Rowe Price Group Inc pays a 4.39% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TROW | |
|---|---|---|
Market Cap | $826.08M | $25.40B |
Sector | Health | Financials |
52-Week High | $30.81 | $120.16 |
52-Week Low | $16.87 | $86.19 |
Enterprise Value | $1.22B | $22.11B |
Dividend Yield | — | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
T. Rowe Price (TROW) trades at $118.55, up 1.28% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 28.28% net income margin and a P/E of 12.72, indicating potential undervaluation. Recent earnings have mostly beaten expectations, and the company maintains robust cash flow, supporting a sustainable dividend. Strategic enhancements to its institutional business and positive media coverage highlight ongoing growth initiatives.
The outlook for TROW is positive, driven by solid fundamentals and strategic positioning, though investor caution is warranted given the majority hold rating from analysts and competitive pressures in asset management. Upside potential exists if the company continues to exceed earnings estimates and manage equity outflows effectively, but macroeconomic volatility remains a key risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
